24 May 2022 : Review article
A Systematic Review of the Literature on Chronic Kidney Disease Following Liver Transplantation
Hitomi Miyata1ADE*, Yoshiaki Morita2ADE, Anil Kumar3DEDOI: 10.12659/AOT.935170
Ann Transplant 2022; 27:e935170
Background
Protocol and Registration
Eligibility Criteria and Study Selection Process
Information Sources and Search Strategy
Data Collection Process and Summary Measures
Data Items and Outcomes
Risk of Bias in Individual Studies
Grading of Included Studies
Study Selection
Baseline Characteristics
Immunosuppressive Treatment
Renal Function
CKD Incidence/Prevalence and Stage
Patient and Graft Survival
Graft Rejection
Diabetes
Risk of Bias Across Studies
Discussion
Conclusions
References
Supplementary Table 2 Incidence or prevalence of diabetes for the included studies.
Author, year [ref] | Study arm | n | Definition of diabetes | Timepoint | Population, n | Incidence or prevalence of diabetes, n (%) |
---|---|---|---|---|---|---|
Gojowy D et al, 2020 []24 | 130 | Based on medical records | Baseline | – | 63 (48.5) | |
Levitsky J et al, 2020 []25 | 28 | – | Baseline (at transplantation) | – | 7 (25.0) | |
32 | Baseline (at transplantation) | – | 7 (21.9) | |||
Lladó L et al, 2019 []26 | 69 | Pre transplantation: clinical history. NODM: use of insulin for >30 consecutive days, plasma glucose ≥200 mg/dL with diabetes symptoms, fasting plasma glucose ≥126 mg/dL, and/or fasting plasma glucose >200 mg/dL after 75 g glucose challenge | Baseline | – | 15 (21.7) | |
12 months (NODM) | – | 19 (27.5) | ||||
Jochmans I et al, 2017 []28 | 21 | – | Baseline | – | 4 (19.0) | |
59 | Baseline | – | 12 (20.3) | |||
Dopazo C et al, 2018 []29 | 20 | – | Baseline | – | 10 (50.0) | |
Pascher A et al, 2015 []30 | 49 | NODM assumed if: two consecutive fasting plasma glucose ≥7.0 mmol/L after day 30, or HbA1c >6.5% (from day 75 onward) | 6 months | SAF, 48 | 13 (40.6) | |
51 | 6 months | SAF, 53 | 17 (42.5) | |||
49 | 6 months | SAF, 45 | 13 (41.9) | |||
51 | 6 months | SAF, 52 | 16 (38.1) | |||
Sharma P et al, 2019 []7 | 93 | – | Baseline | – | 33 (35.5) | |
Lim Y-T et al, 2020 []19 | 78 | Fasting glycemia repeatedly >126 mg/dL, glycated hemoglobin ≥6.5% or oral hypoglycemic or insulin treatment (based on WHO criteria) | Baseline | 75 | 15 (20.0) | |
6 months (NODM) | 53 | 5 (9.4) | ||||
Saliba F et al, 2017 []22 | 93 | Fasting glycemia ≥126 mg/dL and/or treatment with a hypoglycemic agent | Baseline | Randomized | 26 (28.0) | |
95 | Baseline | Randomized | 28 (29.5) | |||
Chauhan KC et al, 2018 []20 | 290 | – | Baseline | 290 | 96 (33.1) | |
223 | Baseline | 223 | 67 (30.0) | |||
67 | Baseline | 67 | 29 (43.3) | |||
149 | Baseline | 149 | 40 (26.9) | |||
141 | Baseline | 141 | 56 (39.7) | |||
AKI – acute kidney injury; ATG – anti-human T-lymphocyte globulin; BID – twice daily; CKD – chronic kidney disease; CsA – ciclosporin A; EC-MPS – enteric-coated mycophenolate sodium; eGFR – estimated glomerular filtration rate; HbA1c – hemoglobin A1c; MMF – mycophenolate mofetil; NODM – new-onset diabetes mellitus; OLT – orthotopic liver transplantation; QD – once daily; SAF – safety analysis set; TAC – tacrolimus. |